In this retrospective study, investigators included adults with relapsed or refractory diffuse large B-cell lymphoma who received loncastuximab tesirine monotherapy as third or fourth line treatment after progressing on second line or third line chimeric antigen receptor T-cell therapy (CAR-T), respectively.
[Blood Cancer Journal]
